Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
This makes retatrutide the first triple-receptor agonist to reach late-stage clinical trials, representing the next step in the evolution of incretin-based metabolic research compounds
Communication with the prescribing clinician is essential before making any dose adjustments, as this may affect glycemic control or weight management outcomes
Clinical trials demonstrate that semaglutide can produce approximately 15% body weight reduction over 68 weeks, while tirzepatide can achieve about 21% reduction over 72 weeks when combined with lifestyle modifications in people without diabetes
As body weight decreases, the dose of levothyroxine needed to maintain euthyroidism may also decrease
US$ 23.79
US$ 21.56
US$ 24.63
